Search
ROX-888
go.drugbank.com/drugs/DB05364ExperimentalROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.
Actelion-1
go.drugbank.com/drugs/DB05367ExperimentalActelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Categories: Endothelin A Receptor AntagonistsRagweed pollen extract
go.drugbank.com/drugs/DB05368ApprovedWithdrawnThe company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.
HZT-501
go.drugbank.com/drugs/DB05369InvestigationalHZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. … HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.
Chlorfenson
go.drugbank.com/drugs/DB05377ExperimentalChlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.
DOTMP HO-166
go.drugbank.com/drugs/DB05380ExperimentalSRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in
INS 316
go.drugbank.com/drugs/DB05390ExperimentalINS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.
Liposomal prostaglandin E1
go.drugbank.com/drugs/DB05391InvestigationalLiposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.
TBC-3711
go.drugbank.com/drugs/DB05407InvestigationalTBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Categories: Endothelin A Receptor AntagonistsNCX 701
go.drugbank.com/drugs/DB05409ExperimentalNitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.